Tildrakizumab Safe, Efficacious for Treating Active Psoriatic Arthritis
A phase 2b study showed that tildrakizumab was significantly more efficacious than placebo in treatment of joint and skin manifestations of psoriatic arthritis by week 24.
A phase 2b study showed that tildrakizumab was significantly more efficacious than placebo in treatment of joint and skin manifestations of psoriatic arthritis by week 24.
Open-label head-to-head trial compared efficacy and safety of ixekizumab with adalimumab in patients with psoriatic arthritis naive to biologic disease-modifying anti-rheumatic drugs.
Investigators examined retrospective data of patients with juvenile idiopathic arthritis and other diseases who received live booster MMR or MMR + varicella while taking disease-modifying antirheumatic drugs, glucocorticosteroids or biological agents.
Study compared efficacy and safety of filgotinib with and without methotrexate in patients with rheumatoid arthritis who were naive to methotrexate therapy.
Investigators sought to determine the efficacy of ultrasound to forecast the development of arthritis among patients with anti-citrullinated protein antibodies with musculoskeletal pain.
MAXIMISE is an ongoing study evaluating the efficacy and safety of secukinumab 300 mg or 150mg in managing axial manifestations in patients with psoriatic arthritis.
As previous studies indicated that all-cause hospitalizations in patients with gout in the United States have overwhelmingly increased by 410% in the last 22 years, researchers sought to determine the potential reasons for the excess hospitalizations.